Streetbeat News

DFCO

Dalrada Financial Corp.

Employees

Industry

Temporary Help Services

Open

0.01

Mkt cap

1.3M

Volume

600

High

0.01

P/E Ratio

-0.04

52-wk high

0.24

Low

0.01

Div yield

N/A

52-wk low

0.00

Dalrada Financial Corporation has announced the addition of Roger Campos to its board of directors. Campos brings extensive business experience and government insight to the company.

Portfolio Pulse from

December 11, 2024 | 1:15 pm

Dalrada Financial Corporation has established a new manufacturing and R&D facility in Portland, Oregon for its subsidiary, Deposition Technology USA, Inc. This move aims to accelerate production and sales of deposition technology products, supporting both North American and global markets.

Portfolio Pulse from

November 21, 2024 | 1:15 pm

Insiders at Dalrada Financial, Research Frontiers, and DBV Technologies have recently made significant stock purchases, indicating potential confidence in their companies' futures. Dalrada Financial's CEO acquired shares amid a 16% stock decline over the past month. Research Frontiers, which recently reported a narrower Q3 loss, saw a director purchase shares. DBV Technologies, announcing promising trial results, also had a director buy shares.

Portfolio Pulse from Avi Kapoor

February 09, 2024 | 11:03 am

Insiders at four companies have recently made notable purchases of their own stock, indicating potential confidence in their companies' prospects. Tharimmune CEO Randy Milby bought 29,000 shares at $0.50 each. Perspective Therapeutics Director Lori A Woods acquired 185,200 shares at $0.27 each. SHF Holdings CEO Sundie Seefried and a Director purchased a total of 39,700 shares at around $0.96 each. Dalrada Financial CEO Brian Bonar bought 9,000 shares at $0.29 each. These transactions can be a factor for investors considering penny stocks.

Portfolio Pulse from Avi Kapoor

December 19, 2023 | 1:29 pm

Insiders at four companies, Glatfelter Corporation (GLT), Dalrada Financial Corporation (DFCO), Lexicon Pharmaceuticals, Inc. (LXRX), and Augusta Gold Corp. (AUGG), have recently made significant share purchases. Glatfelter's 10% owner acquired 236,000 shares, Dalrada's CEO bought 7,300 shares, a director at Lexicon purchased 1,000,000 shares, and Augusta's Executive Chairman bought 15,000 shares. These transactions may indicate the insiders' confidence in their respective companies' prospects.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 12:06 pm

Insiders at Vivani Medical, Dalrada Financial, and Oxbridge Re Holdings have recently purchased shares in their respective companies. Vivani Medical's Director acquired 21,426 shares at an average price of $0.92, Dalrada Financial's CEO bought 10,500 shares at an average price of $0.19, and Oxbridge Re Holdings' 10% owner purchased 100,000 shares at an average price of $1.10.

Portfolio Pulse from Lisa Levin

September 25, 2023 | 1:16 pm

Insiders at four penny stocks, Dalrada Financial Corporation (OTC:DFCO), Gaia, Inc. (NASDAQ:GAIA), Cidara Therapeutics, Inc. (NASDAQ:CDTX), and Augusta Gold Corp. (OTC:AUGG), have recently made notable purchases. Dalrada's CEO acquired 15,000 shares, Gaia's Director bought 9,000 shares, Cidara's President and CEO purchased 50,000 shares, and Augusta's Executive Chairman bought 30,000 shares. These transactions may indicate the insiders' confidence in their companies' prospects.

Portfolio Pulse from Lisa Levin

August 09, 2023 | 12:53 pm

Insiders at Evelo Biosciences, Dalrada Financial Corporation, and Augusta Gold Corp. have recently made significant purchases of their companies' stocks. Noubar Afeyan, a 10% owner of Evelo Biosciences, acquired 5,411,255 shares at an average price of $2.31, costing around $12.5 million. Brian Bonar, CEO of Dalrada Financial, bought 79,550 shares at an average price of $0.14, spending around $11,510. Richard Warke, Executive Chairman of Augusta Gold, purchased 10,000 shares at an average price of $0.78, costing around $7,750.

Portfolio Pulse from Lisa Levin

July 14, 2023 | 11:30 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.